pioglitazone


Also found in: Dictionary, Wikipedia.

pioglitazone

 [pi″o-glit´ah-zōn]
an agent used in treatment of type 2 diabetes mellitis, decreasing insulin resistance in the peripheral tissues and liver, used orally as the hydrochloride salt.

pioglitazone

/pi·o·glit·a·zone/ (pi″o-glit´ah-zōn) an antidiabetic agent that decreases insulin resistance in the peripheral tissues and liver; used as the hydrochloride salt in the treatment of type 2 diabetes mellitus.

pioglitazone

(pī′ō-glĭt′ə-zōn′)
n.
A thiazolidinedione drug, C19H20N2O3S, used in its hydrochloride form to treat type 2 diabetes.

pioglitazone

an oral antidiabetic.
indication It is used to treat stable type 2 diabetes mellitus.
contraindications Lactation, diabetic ketoacidosis, and known hypersensitivity to this drug prohibit its use. It is also contraindicated in children.
adverse effects Common adverse effects include myalgia, sinusitis, upper respiratory infection, pharyngitis, headache, and aggravated diabetes mellitus.

pioglitazone

Actos® Endocrinology An oral antidiabetic that ↓ insulin resistance, used to manage type 2 DM; it inhibits hepatic gluconeogenesis, and improves glycemic control while ↓ circulating insulin Adverse effects Edema, ↑ URIs, headaches, myalgias, sinusitis. See Diabetes mellitus.
References in periodicals archive ?
The rats were randomly assigned to the sham operation group (SO), SAP model group (SAP), and pioglitazone group (Pi).
First and second groups were given a daily dose of tab pioglitazone 30mg and gemfibrozil 600mg, respectively, while the third group served as the healthy control.
Two were taken as interventional groups and received either pioglitazone or telmisartanfor four weeks after induction of diabetes.
Investigators randomized 101 individuals with biopsy-proven nonalcoholic steatohepatitis (NASH) and either prediabetes or type 2 diabetes to 18 months of 45 mg/day pioglitazone or placebo, followed by an 18 month open-label phase of pioglitazone, in addition to a hypocaloric diet.
Investigators randomized 101 individuals with biopsy-proven nonalcoholic steatohepatitis (NASH) and either prediabetes or type 2 diabetes to 18 months of 45 mg/day of pioglitazone or placebo, followed by an 18-month open-label phase of pioglitazone, in addition to a hypocaloric diet.
In this study, stroke or heart attack occurred in 9% of participants taking pioglitazone and 11.
Suchard were commissioned to conduct their analysis by plaintiffs attorneys who are engaged in lawsuits against Takeda regarding use of pioglitazone.
STUDY DESIGN, AIMS AND OBJECTIVES: It was a Prospective, open level, parallel group, observational study where therapeutic efficacy and safety of add-on therapy with Pioglitazone (15mg) and additional Metformin (500mg) was compared in patients having uncontrolled plasma glucose with Glimepiride (2mg) and Metformin (1000mg) daily dose.
Rosiglitazone use was curbed due to heart concerns, although restrictions were later lifted, while pioglitazone was hit by concerns over a possible link to bladder cancer.
In the phase III, randomized, placebo-controlled, double-blind PIVENS trial, vitamin E therapy was compared to pioglitazone and placebo in 247 nondiabetic adults (N.
Tobira Therapeutics, a United States based biopharmaceutical company, has commenced dosing in a Phase I trial to assess the pharmacokinetics and safety in healthy patients of cenicriviroc and the diabetes medication, pioglitazone, both when administered alone and in combination, it was reported yesterday.
M2 PHARMA-January 22, 2015-Tobira Therapeutics starts dosing in Phase I trial of cenicriviroc and pioglitazone